Home GPCR & G Protein Vasopressin Receptor

Vasopressin Receptor Agonists | Antagonists

Isoform-selective Products

Vasopressin Receptor Products

  • All (6)
  • Vasopressin Receptor Antagonists (6)
  • New Vasopressin Receptor Products
Cat.No. Product Name Information Product Use Citations Product Validations
S2593 Tolvaptan Tolvaptan (OPC-41061) is an orally effective nonpeptide arginine vasopressin V2 receptor antagonist with IC50 of 3 nM, used to treat hyponatremia.
J Immunother Cancer, 2024, 12(11)e009805
Int Immunopharmacol, 2024, 127:111378
Acta Physiol (Oxf), 2021, 10.1111/apha.13661
Verified customer review of Tolvaptan
S2116 Conivaptan HCl Conivaptan HCl(YM 087) is an orally active, non-peptide, vasopressin V1A and V2 receptor antagonist, used in the treatment of euvolemic and hypervolemic hyponatremia.
Sci Bull (Beijing), 2024, 69(12):1936-1953
J Immunother Cancer, 2024, 12(11)e009805
Cell Res, 2022, 1-17
Verified customer review of Conivaptan HCl
S2920 Mozavaptan Mozavaptan (OPC-31260) is a novel competitive vasopressin receptor antagonist for both V1 and V2 receptors with IC50 of 1.2 μM and 14 nM, respectively.
Life Sci, 2019, 10.1016/j.lfs.2019.05.049
Am J Med Sci, 2019, 357(3):247-254
S0007 RO 5028442 (RG7713) RO 5028442 (RG7713) is a highly potent and selective Brain-Penetrant Vasopressin 1a (V1a) receptor antagonist with Kis of 1 nM for hV1a and 39 nM for mV1a.
S2815 Lixivaptan (VPA-985) Lixivaptan (VPA-985, CRTX 080, WAY VPA 985) is an oral, non-peptide, selective V2 receptor vasopressin antagonist with IC50s of 1.2 nM and 2.3 nM for human V2 receptor and rat V2 receptor, respectively.
E4957 Mozavaptan (hydrochloride) Mozavaptan hydrochloride(OPC 31260 HCl), a benzazepine derivative is a potent, selective, competitive, and orally active antagonist of vasopressin V2 receptor with an IC50 value of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment.
S2593 Tolvaptan Tolvaptan (OPC-41061) is an orally effective nonpeptide arginine vasopressin V2 receptor antagonist with IC50 of 3 nM, used to treat hyponatremia.
J Immunother Cancer, 2024, 12(11)e009805
Int Immunopharmacol, 2024, 127:111378
Acta Physiol (Oxf), 2021, 10.1111/apha.13661
 Verified customer review of Tolvaptan
S2116 Conivaptan HCl Conivaptan HCl(YM 087) is an orally active, non-peptide, vasopressin V1A and V2 receptor antagonist, used in the treatment of euvolemic and hypervolemic hyponatremia.
Sci Bull (Beijing), 2024, 69(12):1936-1953
J Immunother Cancer, 2024, 12(11)e009805
Cell Res, 2022, 1-17
 Verified customer review of Conivaptan HCl
S2920 Mozavaptan Mozavaptan (OPC-31260) is a novel competitive vasopressin receptor antagonist for both V1 and V2 receptors with IC50 of 1.2 μM and 14 nM, respectively.
Life Sci, 2019, 10.1016/j.lfs.2019.05.049
Am J Med Sci, 2019, 357(3):247-254
S0007 RO 5028442 (RG7713) RO 5028442 (RG7713) is a highly potent and selective Brain-Penetrant Vasopressin 1a (V1a) receptor antagonist with Kis of 1 nM for hV1a and 39 nM for mV1a.
S2815 Lixivaptan (VPA-985) Lixivaptan (VPA-985, CRTX 080, WAY VPA 985) is an oral, non-peptide, selective V2 receptor vasopressin antagonist with IC50s of 1.2 nM and 2.3 nM for human V2 receptor and rat V2 receptor, respectively.
E4957 Mozavaptan (hydrochloride) Mozavaptan hydrochloride(OPC 31260 HCl), a benzazepine derivative is a potent, selective, competitive, and orally active antagonist of vasopressin V2 receptor with an IC50 value of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment.

Signaling Pathway Map